Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03805594
Title 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors University of California, San Francisco
Indications

prostate adenocarcinoma

Therapies

lutetium Lu 177 vipivotide tetraxetan + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.